| Description |
Sarpogrelate (MCI-9042) is a new, specific orally active 5-HT2 receptor antagonist, Sarpogrelate (MCI-9042) increases platelet aggregation and has hemostasis effect, and can be used for the research of Buerger’s disease[1].
|
| Related Catalog |
|
| Target |
5-HT2 Receptor
|
| In Vitro |
Sarpogrelate (MCI-9042) induces a significant decrease in plasma serotonin (5-HT) concentration and after 2 weeks increases significantly the concentration of whole blood 5-HT. Sarpogrelate (MCI-9042) increases significantly plasma tryptophan concentration after 2 and 4 weeks, and no changes in plasma 5-HIAA concentration. Sarpogrelate (MCI-9042) also has a tendency to increase the concentration of whole blood tryptophan concentration, did not show significant changes in platelet aggregation induced by ADP and collagen. Sarpogrelate (MCI-9042) increases significantly platelet aggregation induced by serotonin after 2 weeks[1].
|
| References |
[1]. A Rydzewski, et al. The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res. 1996 Dec 15;84(6):445-52.
|
